Hemogenyx Raises Capital via Warrant Exercise
LONDON, U.K., Feb. 23, 2026 — Hemogenyx Pharmaceuticals PLC announced the exercise of warrants and subsequent issue of new...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LONDON, U.K., Feb. 23, 2026 — Hemogenyx Pharmaceuticals PLC announced the exercise of warrants and subsequent issue of new...
REYKJAVÍK, ICELAND | December 31, 2025 — Alvotech announced it has secured a USD 100 million senior term loan...
Florham Park, New Jersey | December 22, 2025 — Celularity Inc., a regenerative and cellular medicine company focused on...
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing therapies for neurodegenerative diseases, has entered into a...
